JP2018503373A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503373A5
JP2018503373A5 JP2017534648A JP2017534648A JP2018503373A5 JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5 JP 2017534648 A JP2017534648 A JP 2017534648A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5
Authority
JP
Japan
Prior art keywords
expression level
determined
cancer
correlates
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067878 external-priority patent/WO2016109546A2/en
Publication of JP2018503373A publication Critical patent/JP2018503373A/ja
Publication of JP2018503373A5 publication Critical patent/JP2018503373A5/ja
Priority to JP2021031306A priority Critical patent/JP7325463B2/ja
Pending legal-status Critical Current

Links

JP2017534648A 2014-12-30 2015-12-29 がんの予後診断及び治療のための方法及び組成物 Pending JP2018503373A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021031306A JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098055P 2014-12-30 2014-12-30
US62/098,055 2014-12-30
PCT/US2015/067878 WO2016109546A2 (en) 2014-12-30 2015-12-29 Methods and compositions for prognosis and treatment of cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021031306A Division JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2018503373A JP2018503373A (ja) 2018-02-08
JP2018503373A5 true JP2018503373A5 (enExample) 2019-01-31

Family

ID=55315702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534648A Pending JP2018503373A (ja) 2014-12-30 2015-12-29 がんの予後診断及び治療のための方法及び組成物
JP2021031306A Active JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021031306A Active JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Country Status (5)

Country Link
US (2) US11236394B2 (enExample)
EP (1) EP3240908A2 (enExample)
JP (2) JP2018503373A (enExample)
CN (1) CN107208138A (enExample)
WO (1) WO2016109546A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
JP7250674B2 (ja) * 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
EP3546591A4 (en) * 2016-11-24 2020-08-12 Daiichi Sankyo Company, Limited METHOD FOR PREDICTING SUSCEPTIBILITY OF CANCER TO TREATMENT WITH A PD-1 IMMUNE CHECKPOINT INHIBITOR
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
EP3333268A1 (en) * 2016-12-09 2018-06-13 Institut Paoli Calmettes Biomarker panel for prognosis of bladder cancer
WO2018122249A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
US20200095643A1 (en) * 2017-02-07 2020-03-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Tim-3 for assessing the severity of cancer
CN106950371B (zh) * 2017-02-17 2019-03-08 张灏 Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途
CA3052670A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11322226B2 (en) 2017-06-13 2022-05-03 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
KR102348291B1 (ko) * 2017-06-14 2022-01-07 연세대학교 산학협력단 암 환자의 치료 반응성을 예측하는 방법
WO2018232142A1 (en) 2017-06-14 2018-12-20 Icahn School Of Medicine At Mount Sinai Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
AU2018301704A1 (en) * 2017-07-14 2020-03-05 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
WO2019117132A1 (ja) * 2017-12-12 2019-06-20 地方独立行政法人神奈川県立病院機構 がん免疫療法の予後予測のためのバイオマーカー
AU2019275404A1 (en) * 2018-05-21 2020-12-03 Bruker Spatial Biology, Inc. Molecular gene signatures and methods of using same
CN108823309B (zh) * 2018-06-11 2021-11-30 北京大学人民医院 检测kiaa0125基因表达水平的物质在辅助鉴定急性淋巴细胞白血病中的应用
GB201810190D0 (en) * 2018-06-21 2018-08-08 Cancer Research Tech Ltd Prognostic and treatment response predictive method
KR20250025409A (ko) * 2018-08-08 2025-02-21 세다르스-신나이 메디칼 센터 암 및 자가면역 질환을 치료하기 위한 조성물
KR102084196B1 (ko) 2018-08-29 2020-03-03 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
WO2020056045A1 (en) * 2018-09-13 2020-03-19 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2019394940A1 (en) * 2018-12-05 2021-06-24 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
CN109880894A (zh) * 2019-03-05 2019-06-14 杭州西合森医学检验实验室有限公司 基于RNAseq的肿瘤免疫微环境预测模型的构建方法
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US20220177978A1 (en) * 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020207771A1 (en) * 2019-04-10 2020-10-15 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
CN114174538A (zh) * 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
US20220241263A1 (en) * 2019-06-01 2022-08-04 Ares Trading S.A. Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes
KR102042710B1 (ko) * 2019-07-02 2019-11-08 의료법인 성광의료재단 면역체크 포인트와 관련된, 난소암 진단용 바이오마커
CN110804642B (zh) * 2019-09-10 2022-06-21 清华大学 Gpr174免疫学功能及其用途
WO2021107452A1 (ko) * 2019-11-29 2021-06-03 의료법인 성광의료재단 면역 세포 치료제에 대한 치료 반응성 예측용 바이오마커
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CN111500733B (zh) * 2020-05-27 2022-03-08 中国人民解放军军事科学院军事医学研究院 外周血单核细胞中用于非小细胞肺癌早期诊断的分子标记物
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
KR102647295B1 (ko) * 2020-09-03 2024-03-14 한국과학기술연구원 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도
WO2022053065A1 (zh) * 2020-09-14 2022-03-17 信达生物制药(苏州)有限公司 用于预测或评估肺癌患者的生物标志物、检测方法及应用
EP4247980A4 (en) * 2020-11-19 2024-10-02 Tempus AI, Inc. DETERMINATION OF CYTOTOXIC GENE SIGNATURE AND ASSOCIATED SYSTEMS AND METHODS FOR PREDICTING RESPONSE AND TREATMENT
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
EP4026918A1 (en) * 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
CN112831562A (zh) * 2021-01-25 2021-05-25 浙江科技学院 一种用于预测肝癌患者切除术后复发风险的生物标志物组合、试剂盒
US20240344138A1 (en) * 2021-03-25 2024-10-17 Feng Biosciences, Inc Targeted therapies in cancer
WO2022211620A1 (en) * 2021-04-01 2022-10-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Cd4/il-2 biomarker.
US20240336975A1 (en) 2021-07-15 2024-10-10 Vib Vzw Biomarkers Predicting Response of Breast Cancer to Immunotherapy
JP7480754B2 (ja) 2021-07-19 2024-05-10 トヨタ自動車株式会社 蓄電装置
TW202320848A (zh) 2021-07-28 2023-06-01 美商建南德克公司 治療癌症之方法及組成物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
EP4526470A1 (en) * 2022-05-19 2025-03-26 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
KR20240051492A (ko) * 2022-10-13 2024-04-22 주식회사 네오셀라 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법
KR20250163916A (ko) 2023-03-06 2025-11-21 제넨테크, 인크. 비소세포 폐암의 예후 및 치료 방법
JPWO2024225488A1 (enExample) * 2023-04-27 2024-10-31
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
HU216142B (hu) 1994-07-21 1999-04-28 Akzo Nobel N.V. Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
AU2010282340B2 (en) * 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EP2484762A4 (en) * 2009-10-02 2013-03-27 Univ Kurume METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON A CANCER PATIENTS AND / OR FORECASTING AFTER IMMUNOTHERAPY AND THE KIT AND KIT THEREFOR
WO2011094483A2 (en) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
EP3072961A1 (en) 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP2601314A4 (en) * 2010-08-04 2013-12-11 Med Biogene Inc PROGNOSTIC SIGNATURES FOR NON-SMALL LUNG CANCER
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP2615181A1 (en) * 2012-01-10 2013-07-17 Universite Joseph Fourier - Grenoble 1 Cyclon expression for the identification and control of cancer cells
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
DK2880180T3 (en) * 2012-08-06 2019-01-14 Inst Nat Sante Rech Med METHODS AND KITS TO SCREEN PATIENTS WITH CANCER
EP2920325A2 (en) * 2012-11-15 2015-09-23 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent

Similar Documents

Publication Publication Date Title
Gavrielatou et al. Biomarkers for immunotherapy response in head and neck cancer
Galon et al. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
JP7430136B2 (ja) 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物
RU2017119231A (ru) Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
JP6815992B2 (ja) キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
JP2017536842A5 (enExample)
Badoual et al. PD-1–expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
Grenga et al. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis
JP2021521137A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
EP4104187A1 (en) Method of predicting response to chimeric antigen receptor therapy
CN112703012A (zh) 治疗癌症的方法
WO2019036724A2 (en) CELLULAR THERAPIES TARGETING MOLECULAR MEDIATORS ASSOCIATED WITH DISEASE, FIBROUS, INFLAMMATORY, AND AUTOIMMUNE CONDITIONS
JP2023508947A (ja) 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム
CN112805378A (zh) 用于评估整合核酸的方法
CN115427069A (zh) 减小遗传抽样中的统计偏差
CN113710274A (zh) 用于预测癌症免疫疗法中的长期存活的方法及组合物
Watson et al. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Wang et al. Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies
WO2019224385A2 (en) Combined bispecific antibody and immuno-oncology therapies
KR101968452B1 (ko) 면역요법 효능의 임상적 상관물
Guo et al. Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response
Sivakumar et al. Single-cell immune multi-omics and repertoire analyses in pancreatic ductal adenocarcinoma reveal differential immunosuppressive mechanisms within different tumour microenvironments
WO2023081894A2 (en) Pre-effector car-t cell gene signatures
Le et al. TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas
Mestrallet Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade